Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 108451, 11 pages
http://dx.doi.org/10.1155/2015/108451
Review Article

Bone-Immune Cell Crosstalk: Bone Diseases

1Department of Clinical and Experimental Medicine, University of Foggia, 71100 Foggia, Italy
2Department of Medical Science, Section of Gerontology and Bone Metabolism Diseases, University of Torino, 10126 Torino, Italy
3Department of Orthopedics, Washington University School of Medicine, St. Louis, MO 63110, USA
4Department of Basic Medical Sciences, Neurosciences and Sense Organs, Section of Human Anatomy and Histology, University of Bari, 70124 Bari, Italy

Received 17 October 2014; Revised 22 January 2015; Accepted 25 January 2015

Academic Editor: Chikao Morimoto

Copyright © 2015 Giorgio Mori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. J. Raggatt and N. C. Partridge, “Cellular and molecular mechanisms of bone remodeling,” The Journal of Biological Chemistry, vol. 285, no. 33, pp. 25103–25108.
  2. R. Tamma and A. Zallone, “Osteoblast and osteoclast crosstalks: from OAF to Ephrin,” Inflammation and Allergy—Drug Targets, vol. 11, no. 3, pp. 196–200, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Mori, P. D'Amelio, R. Faccio, and G. Brunetti, “The interplay between the bone and the immune system,” Clinical and Developmental Immunology, vol. 2013, Article ID 720504, 16 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Sato, A. Suematsu, K. Okamoto et al., “Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction,” Journal of Experimental Medicine, vol. 203, no. 12, pp. 2673–2682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. I. E. Adamopoulos, C. C. Chao, R. Geissler et al., “Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors,” Arthritis Research and Therapy, vol. 12, no. 1, article R29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Sato and H. Takayanagi, “Osteoclasts, rheumatoid arthritis, and osteoimmunology,” Current Opinion in Rheumatology, vol. 18, no. 4, pp. 419–426, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. B. Berezow and R. P. Darveau, “Microbial shift and periodontitis,” Periodontology 2000, vol. 55, no. 1, pp. 36–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. E. Petersen and H. Ogawa, “Strengthening the prevention of periodontal disease: the WHO approach,” Journal of Periodontology, vol. 76, no. 12, pp. 2187–2193, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Gemmell and G. J. Seymour, “Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease,” Periodontology 2000, vol. 35, pp. 21–41, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Saxén, “Heredity of juvenile periodontitis,” Journal of Clinical Periodontology, vol. 7, no. 4, pp. 276–288, 1980. View at Publisher · View at Google Scholar · View at Scopus
  11. B. S. Michalowicz, D. Aeppli, J. G. Virag et al., “Periodontal findings in adult twins,” Journal of Periodontology, vol. 62, no. 5, pp. 293–299, 1991. View at Publisher · View at Google Scholar · View at Scopus
  12. C. W. Cutler and R. Jotwani, “Antigen-presentation and the role of dendritic cells in periodontitis,” Periodontology 2000, vol. 35, pp. 135–157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. K. M. Murphy and S. L. Reiner, “The lineage decisions of helper T cells,” Nature Reviews Immunology, vol. 2, no. 12, pp. 933–944, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Oda, H. Yoshie, and K. Yamazaki, “Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-κB ligand in vitro,” Oral Microbiology and Immunology, vol. 18, no. 1, pp. 30–36, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Lin, L. Li, Y. Sun et al., “IL-17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF6/TBK1-JNK/NF-κB pathways,” Immunology, 2014. View at Publisher · View at Google Scholar
  16. G. Brunetti, S. Colucci, P. Pignataro et al., “T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients,” Journal of Periodontology, vol. 76, no. 10, pp. 1675–1680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Kawai, T. Matsuyama, Y. Hosokawa et al., “B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease,” The American Journal of Pathology, vol. 169, no. 3, pp. 987–998, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. T. Weaver and R. D. Hatton, “Interplay between the TH 17 and TReg cell lineages: a co-evolutionary perspective,” Nature Reviews Immunology, vol. 9, no. 12, pp. 883–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Menter, A. Gottlieb, S. R. Feldman et al., “Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics,” Journal of the American Academy of Dermatology, vol. 58, no. 5, pp. 826–850, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Acosta Felquer, L. C. Coates, E. R. Soriano et al., “Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review,” The Journal of Rheumatology, vol. 41, no. 11, pp. 2277–2285, 2014. View at Publisher · View at Google Scholar
  21. G. Brunetti, R. Rizzi, A. Oranger et al., “LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease,” Oncotarget, vol. 5, no. 24, pp. 12950–12967, 2014. View at Google Scholar
  22. M. F. Faienza, V. Luce, A. Lonero et al., “Treatment of osteoporosis in children with glucocorticoid-treated diseases,” Expert Review of Endocrinology & Metabolism, vol. 9, no. 5, pp. 525–534, 2014. View at Publisher · View at Google Scholar
  23. G. A. Clines and T. A. Guise, “Molecular mechanisms and treatment of bone metastasis,” Expert Reviews in Molecular Medicine, vol. 10, article e7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. A. Guise, “Molecular mechanisms of osteolytic bone metastases,” Cancer, vol. 88, no. 12, pp. 2892–2898, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Mazzantini and O. di Munno, “Glucocorticoid-induced osteoporosis: 2013 update,” Reumatismo, vol. 66, no. 2, pp. 144–152, 2014. View at Publisher · View at Google Scholar
  26. H. K. Fizazi, A. Lipton, X. Mariette et al., “Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1564–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. P. Iyer, J. T. Beck, A. K. Stewart et al., “Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events,” British Journal of Haematology, vol. 167, no. 3, pp. 366–375, 2014. View at Publisher · View at Google Scholar
  28. G. Brunetti, M. F. Faienza, L. Piacente et al., “High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 304, no. 5, pp. E546–E554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Gottlieb, A. Menter, A. Mendelsohn et al., “Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial,” The Lancet, vol. 373, no. 9664, pp. 633–640, 2009. View at Google Scholar
  30. K. M. Dhodapkar, S. Barbuto, P. Matthews et al., “Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma,” Blood, vol. 112, no. 7, pp. 2878–2885, 2008. View at Google Scholar
  31. K. Noonan, L. Marchionni, J. Anderson, D. Pardoll, G. D. Roodman, and I. Borrello, “A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma,” Blood, vol. 116, no. 18, pp. 3554–3563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. R. H. Prabhala, D. Pelluru, M. Fulciniti et al., “Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma,” Blood, vol. 115, no. 26, pp. 5385–5392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Davari, M. S. Leo, F. Kamangar et al., “Ustekinumab for the treatment of psoriatic arthritis: an update,” Journal of Clinical, Cosmetic and Investigational Dermatology, vol. 7, pp. 243–249, 2014. View at Google Scholar
  34. E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda, “Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity,” Clinical Cancer Research, vol. 11, no. 18, pp. 6713–6721, 2005. View at Publisher · View at Google Scholar
  35. H.-J. Ko, Y.-J. Kim, Y.-S. Kim et al., “A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model,” Cancer Research, vol. 67, no. 15, pp. 7477–7486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. J. Mease, M. C. Genovese, M. W. Greenwald et al., “Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis,” The New England Journal of Medicine, vol. 370, no. 24, pp. 2295–2306, 2014. View at Publisher · View at Google Scholar
  37. S. Colucci, G. Brunetti, F. P. Cantatore et al., “Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL-7 in an in vitro model derived from human psoriatic arthritis,” Journal of Pathology, vol. 212, no. 1, pp. 47–55, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Infante-Duarte, H. F. Horton, M. C. Byrne, and T. Kamradt, “Microbial lipopeptides induce the production of IL-17 in Th cells,” The Journal of Immunology, vol. 165, no. 11, pp. 6107–6115, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear recepto RORγt directs the differentiation program of pro-inflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Batycka-Baran, J. Maj, R. Wolf, and J. C. Szepietowski, “The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis,” Journal of Immunology Research, vol. 2014, Article ID 628289, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. O. FitzGerald and R. Winchester, “Psoriatic arthritis: from pathogenesis to therapy,” Arthritis Research and Therapy, vol. 11, no. 1, article 214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. L. R. Espinoza, J. L. Aguilar, C. G. Espinoza, M. L. Cuellar, E. Scopelitis, and L. H. Silveira, “Fibroblast function in psoriatic arthritis. I. Alteration of cell kinetics and growth factor responses,” The Journal of Rheumatology, vol. 21, no. 8, pp. 1502–1506, 1994. View at Google Scholar · View at Scopus
  43. L. R. Espinoza, C. G. Espinoza, M. L. Cuellar, E. Scopelitis, L. H. Silveira, and G. R. Grotendorst, “Fibroblast function in psoriatic arthritis. II. Increased expression of β platelet derived growth factor receptors and increased production of growth factor and cytokines,” The Journal of Rheumatology, vol. 21, no. 8, pp. 1507–1511, 1994. View at Google Scholar · View at Scopus
  44. D. D. Gladman, “Toward unraveling the mystery of psoriatic arthritis,” Arthritis and Rheumatism, vol. 36, no. 7, pp. 881–884, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Menon, N. J. Gullick, G. J. Walter et al., “Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression,” Arthritis and Rheumatology, vol. 66, no. 5, pp. 1272–1281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. “Osteoporosis. National Institutes of Health Consensus Development Conference Statement,” National Institutes of Health Consensus Development Conference Statement, vol. 5, no. 3, p. 6, 1984.
  47. P. D'Amelio, A. Grimaldi, S. di Bella et al., “Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis,” Bone, vol. 43, no. 1, pp. 92–100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. P. D'Amelio, M. A. Cristofaro, A. Grimaldi et al., “The role of circulating bone cell precursors in fracture healing,” Calcified Tissue International, vol. 86, no. 6, pp. 463–469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. P. D'Amelio, A. Grimaldi, M. A. Cristofaro et al., “Alendronate reduces osteoclast precursors in osteoporosis,” Osteoporosis International, vol. 21, no. 10, pp. 1741–1750, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. L. D'amico, M. A. Satolli, C. Mecca et al., “Bone metastases in gastric cancer follow a RANKL-independent mechanism,” Oncology Reports, vol. 29, no. 4, pp. 1453–1458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Roato, P. D'Amelio, E. Gorassini et al., “Osteoclasts are active in bone forming metastases of prostate cancer patients,” PLoS ONE, vol. 3, no. 11, Article ID e3627, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. A. E. Oostlander, V. Everts, T. Schoenmaker et al., “T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for crohn's disease-associated bone loss,” Journal of Cellular Biochemistry, vol. 113, no. 1, pp. 260–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Reed, R. J. Baker, A. B. Mehta, and D. A. Hughes, “Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease,” Blood Cells, Molecules, & Diseases, vol. 51, no. 3, pp. 185–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Pacifici, “The immune system and bone,” Archives of Biochemistry and Biophysics, vol. 503, no. 1, pp. 41–53, 2010. View at Google Scholar
  55. I. Roato, E. Gorassini, G. Brunetti et al., “IL-7 modulates osteoclastogenesis in patients affected by solid tumors,” Annals of the New York Academy of Sciences, vol. 1117, pp. 377–384, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. A. E. Oostlander, V. Everts, T. Schoenmaker et al., “T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss,” Journal of Cellular Biochemistry, vol. 113, no. 1, pp. 260–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Xue, L. Jiang, Q. Cheng et al., “Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions,” PLoS ONE, vol. 7, no. 10, Article ID e46740, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. P. D'Amelio, I. Roato, L. Damico et al., “Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures,” Osteoporosis International, vol. 22, no. 11, pp. 2869–2877, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Udagawa, N. Takahashi, E. Jimi et al., “Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor,” Bone, vol. 25, no. 5, pp. 517–523, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Onal, J. Xiong, X. Chen et al., “Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss,” The Journal of Biological Chemistry, vol. 287, no. 35, pp. 29851–29860, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. L. C. Hofbauer, S. Khosla, C. R. Dunstan, D. L. Lacey, W. J. Boyle, and B. L. Riggs, “The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption,” Journal of Bone and Mineral Research, vol. 15, no. 1, pp. 2–12, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Y. Kong, H. Yoshida, I. Sarosi et al., “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,” Nature, vol. 397, no. 6717, pp. 315–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Hotokezaka, E. Sakai, N. Ohara et al., “Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan,” Journal of Cellular Biochemistry, vol. 101, no. 1, pp. 122–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Wei, H. Kitaura, P. Zhou, F. P. Ross, and S. L. Teitelbaum, “IL-1 mediates TNF-induced osteoclastogenesis,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 282–290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Charatcharoenwitthaya, S. Khosla, E. J. Atkinson, L. K. McCready, and B. L. Riggs, “Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women,” Journal of Bone and Mineral Research, vol. 22, no. 5, pp. 723–729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Giuliani, S. Colla, R. Sala et al., “Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease,” Blood, vol. 100, no. 13, pp. 4615–4621, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Toraldo, C. Roggia, W.-P. Qian, R. Pacific, and M. N. Weitzmann, “IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 125–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. M. R. Ryan, R. Shepherd, J. K. Leavey et al., “An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 46, pp. 16735–16740, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. A. M. Tyagi, K. Srivastava, M. N. Mansoori, R. Trivedi, N. Chattopadhyay, and D. Singh, “Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis,” PloS ONE, vol. 7, no. 9, Article ID e44552, 2012. View at Google Scholar · View at Scopus
  70. R. Zhao, “Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis,” European Journal of Clinical Investigation, vol. 43, no. 11, pp. 1195–1202, 2013. View at Google Scholar
  71. L. Das Roy, L. B. Pathangey, T. L. Tinder, J. L. Schettini, H. E. Gruber, and P. Mukherjee, “Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis,” Breast Cancer Research, vol. 11, no. 4, article R56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Forsblad d'Elia and H. Carlsten, “The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis,” Scandinavian Journal of Immunology, vol. 68, no. 6, pp. 661–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Kumru, A. Godekmerdan, and B. Yilmaz, “Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women,” Journal of Reproductive Immunology, vol. 63, no. 1, pp. 31–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Anginot, R. Dacquin, M. Mazzorana, and P. Jurdic, “Lymphocytes and the Dap12 adaptor are key regulators of osteoclast activation associated with gonadal failure,” PLoS ONE, vol. 2, no. 7, Article ID e585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. S.-K. Lee, Y. Kadono, F. Okada et al., “T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy,” Journal of Bone and Mineral Research, vol. 21, no. 11, pp. 1704–1712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Cenci, G. Toraldo, M. N. Weitzmann et al., “Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10405–10410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, W. J. Boyle, D. L. Lacey, and B. L. Riggs, “Role of RANK ligand in mediating increased bone resorption in early postmenopausal women,” The Journal of Clinical Investigation, vol. 111, no. 8, pp. 1221–1230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. Y. Gao, F. Grassi, M. R. Ryan et al., “IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 122–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Li, G. Toraldo, A. Li et al., “B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo,” Blood, vol. 109, no. 9, pp. 3839–3848, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Adamski, Z. Ma, S. Nozell, and E. N. Benveniste, “17beta-estradiol inhibits class ii major histocompatibility complex (MHC) expression: influence on histone modifications and CBP recruitment to the class II MHC promoter,” Molecular Endocrinology, vol. 18, no. 8, pp. 1963–1974, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. J. H. Kim, K. Kim, B. U. Youn, H. M. Jin, and N. Kim, “MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR,” Cellular Signalling, vol. 22, no. 9, pp. 1341–1349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. R. B. Mueller, A. Skapenko, M. Grunke et al., “Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor,” Arthritis and Rheumatism, vol. 52, no. 2, pp. 451–460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. J.-Y. Li, H. Tawfeek, B. Bedi et al., “Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 2, pp. 768–773, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Yokoyama, T. Ukai, E. R. Ayon Haro, T. Kishimoto, Y. Yoshinaga, and Y. Hara, “Membrane-bound CD40 ligand on T cells from mice injected with lipopolysaccharide accelerates lipopolysaccharide-induced osteoclastogenesis,” Journal of Periodontal Research, vol. 46, no. 4, pp. 464–474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Bedi, J.-Y. Li, F. Grassi, H. Tawfeek, M. N. Weitzmann, and R. Pacifici, “Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss,” Annals of the New York Academy of Sciences, vol. 1192, pp. 215–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Gao, X. Wu, M. Terauchi et al., “T cells potentiate PTH-induced cortical bone loss through CD40L signaling,” Cell Metabolism, vol. 8, no. 2, pp. 132–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Grčević, I. K. Lukić, N. Kovačić, S. Ivčević, V. Katavić, and A. Marušić, “Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos,” Clinical and Experimental Immunology, vol. 146, no. 1, pp. 146–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. N. Wyzga, S. Varghese, S. Wikel, E. Canalis, and F. A. Sylvester, “Effects of activated T cells on osteoclastogenesis depend on how they are activated,” Bone, vol. 35, no. 3, pp. 614–620, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Y. Kong, U. Feige, I. Sarosi et al., “Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand,” Nature, vol. 402, pp. 304–309, 1999. View at Google Scholar
  90. I. Roato, D. Caldo, L. D'Amico et al., “Osteoclastogenesis in peripheral blood mononuclear cell cultures of periprosthetic osteolysis patients and the phenotype of T cells localized in periprosthetic tissues,” Biomaterials, vol. 31, no. 29, pp. 7519–7525, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Giuliani, F. Morandi, S. Tagliaferri et al., “Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients,” Blood, vol. 107, no. 2, pp. 841–842, 2006. View at Google Scholar
  92. X. Han, X. Lin, A. R. Seliger, J. Eastcott, T. Kawai, and M. A. Taubman, “Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria,” Oral Microbiology and Immunology, vol. 23, no. 3, pp. 190–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Yeo, K.-M. Toellner, M. Salmon et al., “Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 11, pp. 2022–2028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Kanematsu, T. Sato, H. Takai, K. Watanabe, K. Ikeda, and Y. Yamada, “Prostaglandin E-2 induces expression of receptor activator of nuclear factor-B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency,” Journal of Bone and Mineral Research, vol. 15, no. 7, pp. 1321–1329, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. X. Han, X. Lin, X. Yu et al., “Porphyromonas gingivalis infection-associated periodontal bone resorption is dependent on receptor activator of NF-κB ligand,” Infection and Immunity, vol. 81, no. 5, pp. 1502–1509, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. G. Wheater, V. E. Hogan, Y. K. O. Teng et al., “Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis,” Osteoporosis International, vol. 22, no. 12, pp. 3067–3072, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Mazziotti, A. Angeli, J. P. Bilezikian, E. Canalis, and A. Giustina, “Glucocorticoid-induced osteoporosis: an update,” Trends in Endocrinology and Metabolism, vol. 17, no. 4, pp. 144–149, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. R. S. Weinstein, “Clinical practice. Glucocorticoid-induced bone disease,” The New England Journal of Medicine, vol. 365, pp. 62–70, 2011. View at Google Scholar
  99. S. Ikeda, Y. Morishita, H. Tsutsumi et al., “Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs,” Bone, vol. 33, no. 5, pp. 779–787, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. M. F. Faienza, G. Brunetti, S. Colucci et al., “Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 7, pp. 2269–2276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. G. D. Roodman, “Pathogenesis of myeloma bone disease,” Leukemia, vol. 23, no. 3, pp. 435–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Colucci, G. Brunetti, A. Oranger et al., “Myeloma cells suppress osteoblasts through sclerostin secretion,” Blood Cancer Journal, vol. 1, no. 6, article e27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Oranger, G. Brunetti, C. Carbone et al., “Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity,” Journal of Immunology Research. In press.
  104. G. Brunetti, S. Colucci, R. Rizzi et al., “The role of OPG/TRAIL complex in multiple myeloma,” Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 334–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Colucci, G. Brunetti, G. Mori et al., “Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients,” Leukemia, vol. 23, no. 11, pp. 2139–2146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. C.-J. Shen, Z.-H. Yuan, Y.-X. Liu, and G.-Y. Hu, “Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma,” Journal of International Medical Research, vol. 40, no. 2, pp. 556–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. J. R. Edwards, S. G. Sun, R. Locklin et al., “LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 5, pp. 1451–1462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. G. R. Mundy, “Metastasis to bone: causes, consequences and therapeutic opportunities,” Nature Reviews Cancer, vol. 2, no. 8, pp. 584–593, 2002. View at Publisher · View at Google Scholar · View at Scopus
  109. K. N. Weilbaecher, T. A. Guise, and L. K. McCauley, “Cancer to bone: a fatal attraction,” Nature Reviews Cancer, vol. 11, no. 6, pp. 411–425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Clemons, K. A. Gelmon, K. I. Pritchard, and A. H. G. Paterson, “Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art,” Current Oncology, vol. 19, no. 5, pp. 259–268, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. S.-M. Käkönen, K. S. Selander, J. M. Chirgwin et al., “Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways,” The Journal of Biological Chemistry, vol. 277, no. 27, pp. 24571–24578, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Valachis, N. P. Polyzos, R. E. Coleman et al., “Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis,” The Oncologist, vol. 18, no. 4, pp. 353–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. M. He, W. Fan, and X. Zhang, “Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis,” Journal of Hematology and Oncology, vol. 6, no. 1, article 80, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. L. S. Rosen, D. Gordon, M. Kaminski et al., “Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial,” Cancer Journal, vol. 7, no. 5, pp. 377–387, 2001. View at Google Scholar · View at Scopus
  115. L. S. Rosen, D. Gordon, S. Tchekmedyian et al., “Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group,” Journal of Clinical Oncology, vol. 21, no. 16, pp. 3150–3157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. A. T. Stopeck, A. Lipton, J.-J. Body et al., “Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study,” Journal of Clinical Oncology, vol. 28, no. 35, pp. 5132–5139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. X. H.-F. Zhang, X. Jin, S. Malladi et al., “Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma,” Cell, vol. 154, no. 5, pp. 1060–1073, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Feuerer, M. Rocha, L. Bai et al., “Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients,” International Journal of Cancer, vol. 92, no. 1, pp. 96–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  119. J. F. Bromberg, C. M. Horvath, Z. Wen, R. D. Schreiber, and J. E. Darnell Jr., “Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 15, pp. 7673–7678, 1996. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Kumar, “The Bcl-2 family of proteins and activation of the ICE-CED-3 family of proteases: a balancing act in apoptosis?” Cell Death and Differentiation, vol. 4, no. 1, pp. 2–3, 1997. View at Publisher · View at Google Scholar · View at Scopus
  121. Z. Qin and T. Blankenstein, “CD4+ T cell—mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells,” Immunity, vol. 12, no. 6, pp. 677–686, 2000. View at Publisher · View at Google Scholar · View at Scopus
  122. B. N. Bidwell, C. Y. Slaney, N. P. Withana et al., “Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape,” Nature Medicine, vol. 18, no. 8, pp. 1224–1231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. L. D’Amico and I. Roato, “The impact of immune system in regulating bone metastasis formation by osteotropic tumors,” Journal of Immunology Research. In press.
  124. M. J. Smyth, G. P. Dunn, and R. D. Schreiber, “Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity,” Advances in Immunology, vol. 90, pp. 1–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. D. G. DeNardo and L. M. Coussens, “Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression,” Breast Cancer Research, vol. 9, no. 4, article 212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. A. C. Monteiro, A. C. Leal, T. Gonçalves-Silva et al., “T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer,” PLoS ONE, vol. 8, no. 7, Article ID e68171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. J. Sceneay, M. T. Chow, A. Chen et al., “Primary tumor hypoxia recruits CD11b+/Ly6Cmed/ Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche,” Cancer Research, vol. 72, no. 16, pp. 3906–3911, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. B. Almand, J. I. Clark, E. Nikitina et al., “Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer,” The Journal of Immunology, vol. 166, no. 1, pp. 678–689, 2001. View at Publisher · View at Google Scholar · View at Scopus
  129. I. Marigo, L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte, “Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells,” Immunological Reviews, vol. 222, no. 1, pp. 162–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Kusmartsev and D. I. Gabrilovich, “Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species,” Journal of Leukocyte Biology, vol. 74, no. 2, pp. 186–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. P. Liu, J. R. Keller, M. Ortiz et al., “Bcl11a is essential for normal lymphoid development,” Nature Immunology, vol. 4, no. 6, pp. 525–532, 2003. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Mazzoni, V. Bronte, A. Visintin et al., “Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism,” The Journal of Immunology, vol. 168, no. 2, pp. 689–695, 2002. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Kusmartsev, Y. Nefedova, D. Yoder, and D. I. Gabrilovich, “Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species,” The Journal of Immunology, vol. 172, no. 2, pp. 989–999, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Kusmartsev and D. I. Gabrilovich, “Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer,” Cancer and Metastasis Reviews, vol. 25, no. 3, pp. 323–331, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. A.-H. Capietto, S. Kim, D. E. Sanford et al., “Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer,” Journal of Experimental Medicine, vol. 210, no. 11, pp. 2257–2271, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. D. Gao, N. Joshi, H. Choi et al., “Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition,” Cancer Research, vol. 72, no. 6, pp. 1384–1394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. M. L. Ortiz, L. Lu, I. Ramachandran, and D. I. Gabrilovich, “Myeloid-derived suppressor cells in the development of lung cancer,” Cancer Immunology Research, vol. 2, no. 1, pp. 50–58, 2014. View at Google Scholar
  138. I. R. Ramachandran, A. Martner, A. Pisklakova et al., “Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow,” The Journal of Immunology, vol. 190, no. 7, pp. 3815–3823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. J. Zhuang, J. Zhang, S. T. Lwin et al., “Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells,” PLoS ONE, vol. 7, no. 11, Article ID e48871, 2012. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Sawant, J. Deshane, J. Jules et al., “Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer,” Cancer Research, vol. 73, no. 2, pp. 672–682, 2013. View at Publisher · View at Google Scholar · View at Scopus